Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model

Journal of Vascular Surgery

Volumn 39, Issue 2, 2004, Pages 432-439

  Rotmans, Joris I ^a,b   Velema, Evelyn ^a   Verhagen, Hence J M ^a   Blankensteijn, Jan D ^a   De Kleijn, Dominique P V ^a   Stroes, Erik S G ^b   Pasterkamp, Gerard ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BB 2983; COLLAGEN; ELASTIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; POLITEF; SCLEROPROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY; CELL MIGRATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; FIBROBLAST; GRAFT PATENCY; HEMODIALYSIS; JUGULAR VEIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SWINE; VASCULAR SMOOTH MUSCLE; VEIN BLOOD FLOW;

EID: 0842289260     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2003.07.009     Document Type: Article

References (52)

1. Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, et al. Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int 2002;61:305-16.
2. Schwab SJ, Harrington JT, Singh A, Roher R, Shohaib SA, Perrone RD, et al. Vascular access for hemodialysis. Kidney Int 1999;55:2078-90.
3. Roy-Chaudhury P, Kelly BS, Miller MA, Reaves A, Armstrong J, Nanayakkara N, et al. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 2001;59:2325-34.
4. Shi Y, O'Brien JEJ, Mannion JD, Morrison RC, Chung W, Ford A, et al. Remodeling of autologous saphenous vein grafts. The role of perivascular myofibroblasts. Circulation 1997;95:2684-93.
5. Hu Y, Mayr M, Metzler B, Erdel M, Davison F, Xu Q, et al. Both donor and recipient origins of smooth muscle cells in vein graft atherosclerotic lesions. Circ Res 2002;91:e13-e20.
6. de Kleijn DP, Sluijter JP, Smit J, Velema E, Richard W, Schoneveld AH, et al. Furin and membrane type-1 metalloproteinase mRNA levels and activation of metalloproteinase-2 are associated with arterial remodeling. FEBS Lett 2001;501:37-41.
7. Southgate KM, Mehta D, Izzat MB, Newby AC, Angelini GD, et al. Increased secretion of basement membrane-degrading metalloproteinases in pig saphenous vein into carotid artery interposition grafts. Arterioscler Thromb Vasc Biol 1999;19:1640-9.
8. Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GI, Welgus HG, et al. Human 92- and 72-kilodalton type IV collagenases are elastases. J Biol Chem 1991;266:7870-5.
9. Nikkari ST, Hoyhtya M, Isola J, Nikkari T. Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol 1996;149:1427-33.
10. Karnik SK, Brooke BS, Bayes-Genis A, Sorensen L, Wythe JD, Schwartz RS, et al. A critical role for elastin signaling in vascular morphogenesis and disease. Development 2003;130:411-23.
11. Barolet AW, Nili N, Cheema A, Robinson R, Natarajan MK, O-Blenes S, et al. Arterial elastase activity after balloon angioplasty and effects of elafin, an elastase inhibitor. Arterioscler Thromb Vasc Biol 2001;21:1269-74.
12. Waugh JM, Li-Hawkins J, Yuksel E, Citra PN, Amabile PG, Hilfiker PR, et al. Therapeutic elastase inhibition by alpha-1-antitrypsin gene transfer limits neointima formation in normal rabbits. J Vasc Interv Radiol 2001;12:1203-9.
13. Hu Y, Baker AH, Zou Y, Newby AC, Xu Q. Local gene transfer of tissue inhibitor of metalloproteinase-2 influences vein graft remodeling in a mouse model. Arterioscler Thromb Vasc Biol 2001;21:1275-80.
14. George SJ, Lloyd CT, Angelini GD, Newby AC, Baker AH. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000;101:296-304.
15. National Institutes of Health. Guide for the Care and Use of Laboratory Animals. Rockville, Md: National Institutes of Health (NIH Publication No. 85-23, 1996).
16. Perree J, van Leeuwen T, Velema E, Smeets M, de Kleijn D, Borst C, et al. UVB-activated psoralen reduces luminal narrowing after balloon dilation because of inhibition of constrictive remodeling. Photochem Photobiol 2002;75:68-75.
17. Newby AC, Southgate KM, Davies M. Extracellular matrix degrading metalloproteinases in the pathogenesis of arteriosclerosis. Basic Res 1994;89(suppl 1):59-70.
18. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90:251-62.
19. George SJ, Zaltsman AB, Newby AC. Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. Cardiovasc Res 1997;33:447-59.
20. Patterson MA, Leville CD, Hower CD, Jean-Claude JM, Seabrook GR, Towne JB, et al. Shear force regulates matrix metalloproteinase activity in human saphenous vein organ culture. J Surg Res 2001;95:67-72.
21. Loth F, Jones SA, Zarins CK, Giddens DP, Nassar RF, Glagov S, et al. Relative contribution of wall shear stress and injury in experimental intimal thickening at PTFE end-to-side arterial anastomoses. J Biomech Eng 2002;124:44-51.
22. Chesler NC, Ku DN, Galis ZS. Transmural pressure induces matrix-degrading activity in porcine arteries ex vivo. Am J Physiol 1999;277: H2002-H2009.
23. Bassiouny HS, Song RH, Hong XF, Singh A, Kocharyan H, Glagov S. Flow regulation of 72-kD collagenase IV (MMP-2) after experimental arterial injury. Circulation 1998;98:157-63.
24. Bendeck MP, Conte M, Zhang M, Nili N, Strauss BH, Farwell SM, et al. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol 2002;160:1089-95.
25. Forough R, Koyama N, Hasenstab D, Lea H, Clowes M, Nikkari ST, et al. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res 1996;79:812-20.
26. Cheng L, Mantile G, Pauly R, Nater C, Felici A, Monticone R, et al. Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation 1998;98:2195-201.
27. Porter KE, Thompson MM, Loftus IM, McDermott E, Jones L, Crowther M, et al. Production and inhibition of the gelatinolytic matrix metalloproteinases in a human model of vein graft stenosis. Eur J Vasc Endovasc Surg 1999;17:404-12.
28. Perktold K, Leuprecht A, Prosi M, Berk T, Czerny M, Trubel W, et al. Fluid dynamics, wall mechanics, and oxygen transfer in peripheral bypass anastomoses. Ann Biomed Eng 2002;30:447-60.
29. Piorko D, Knez P, Nelson K, Schmitz-Rixen T. Compliance in anastomoses with and without vein cuff interposition. Eur J Vasc Endovasc Surg 2001;21:461-6.
30. Pappas PJ, Hobson RW II, Meyers MG, Jamil Z, Lee BC, Silva MB, et al. Patency of infrainguinal polytetrafluoroethylene bypass grafts with distal interposition vein cuffs. Cardiovasc Surg 1998;6:19-26.
31. Forough R, Lea H, Starcher B, Allaire E, Clowes M, Hasenstab D, et al. Metalloproteinase blockade by local overexpression of TIMP-1 increases elastin accumulation in rat carotid artery intima. Arterioscler Thromb Vasc Biol 1998;18:803-7.
32. Amabile PG, Wong H, Uy M, Bronmand S, Elkins CJ, Yuksel E, et al. In vivo vascular engineering of vein grafts: directed migration of smooth muscle cells by perivascular release of elastase limits neointimal proliferation. J Vasc Interv Radiol 2002;13:709-15.
33. Wong AH, Waugh JM, Amabile PG, Yuksel E, Dake MD. In vivo vascular engineering: directed migration of smooth muscle cells to limit neointima. Tissue Eng 2002;8:189-99.
34. Hance KA, Tataria M, Ziporin SJ, Lee JK, Thompson RW. Monocyte chemotactic activity in human abdominal aortic aneurysms: role of elastin degradation peptides and the 67-kD cell surface elastin receptor. J Vasc Surg 2002;35:254-61.
35. de Smet BJ, de Kleijn D, Hanemaaijer R, Verheijen JH, Robertus L, van der Helm YJ, et al. Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty: a study in the atherosclerotic Yucatan micropig. Circulation 2000;101:2962-7.
36. Strauss BH, Robinson R, Batchelor WB, Chisholm RJ, Ravi G, Natarajan MK, et al. In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Circ Res 1996;79:541-50.
37. Kuzuya M, Asai T, Kanda S, Maeda K, Cheng XW, Iguchi A. Glycation cross-links inhibit matrix metalloproteinase-2 activation in vascular smooth muscle cells cultured on collagen lattice. Diabetologia 2001;44:433-6.
38. Uzel MI, Scott IC, Babakhanlou-Chase H, Palamakumbura AH, Pappano WN, Hong HH, et al. Multiple bone morphogenetic protein 1-related mammalian metalloproteinases process pro-lysyl oxidase at the correct physiological site and control lysyl oxidase activation in mouse embryo fibroblast cultures. J Biol Chem 2001;276:22537-43.
39. Amano S, Akutsu N, Matsunaga Y, Nishiyama T, Champliaud MF, Burgeson RE, et al. Importance of balance between extracellular matrix synthesis and degradation in basement membrane formation. Exp Cell Res 2001;271:249-62.
40. Martin J, Yung S, Robson RL, Steadman R, Davies M. Production and regulation of matrix metalloproteinases and their inhibitors by human peritoneal mesothelial cells. Perit Dial Int 2000;20:524-33.
41. Lombard MA, Wallace TL, Kubicek MF, Petzold GL, Mitchell MA, Hendges SK, et al. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-alpha receptors in a human colon adenocarcinoma (Colo 205) cell line. Cancer Res 1998;58:4001-7.
42. Yao J, Bone RC, Sawhney RS. Differential effects of tumor necrosis factor-alpha on the expression of fibronectin and collagen genes in cultured bovine endothelial cells. Cell Mol Biol Res 1995;41:17-28.
43. Bennett MR. Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. Cardiovasc Res 1999;41:361-8.
44. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995;182:1777-83.
45. Black R, Rauch C, Kozlosky C, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-33.
46. Balcom JH, Keck T, Warshaw AL, et al. Perioperative matrix metalloproteinase inhibition therapy does not impair wound or anastomotic healing. J Gastrointest Surg 2002;6:488-95.
47. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 1996;78:38-43.
48. Sho E, Sho M, Singh TM, Nanjo H, Komatsu M, Xu C, et al. Arterial enlargement in response to high flow requires early expression of matrix metalloproteinases to degrade extracellular matrix. Exp Mol Pathol 2002;73:142-53.
49. U.S. Renal Data System. USRDS 2002 Annual Data Report: atlas of end-stage renal disease in the United States. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2002.
50. Kennedy R, Case C, Fathi R, Johnson D, Isbel N, Marwick TH, et al. Does renal failure cause an atherosclerotic milieu in patients with end-stage renal disease? Am J Med 2001;110:198-204.
51. Cheung AK, Sarnak MJ, Yan G, Swyer JT, Heyka RJ, Rocco MV, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000;58:353-62.
52. Steward WP, Thomas AI. Marimastat: the clinical development of a matrix metalloproteinase inhibitor. Expert Opin Investig Drugs 2000;9:2913-22.